MAGED2 (MAGE Family Member D2) is a member of the MAGED gene family. The MAGED genes are clustered on chromosome Xp11. MAGED2 is located in Xp11.2, a hot spot for X-linked intellectual disability (XLID). Mutations in MAGED2 cause a form of transient antenatal Bartter's syndrome. MAGED2 may also be involved in several types of cancer, including breast cancer and melanoma. The protein encoded by MAGED2 is progressively recruited from the cytoplasm to the nucleoplasm during the interphase and after nucleolar stress and is thus thought to play a role in cell cycle regulation. Alternative splicing results in multiple transcript variants.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000 ELISA 1:5000-20000.

MAGD2 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at https://www.abbkine.com/product/magd2-polyclonal-antibody-abp59203/

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.